0
Allergy and Airway |

Exacerbations, Emergency Visits, and Hospitalizations in Patients Receiving Omalizumab in Real World Settings: A Systematic Literature Review of Nonrandomized Studies

Jonathan Corren, MD; Susan Gabriel; Tom Karagiannis, PharmD; Kimberly Ruiz; Bethany Sawchyn, PharmD; Jennifer Colby, PharmD; Meryl Mendelson, MD
Author and Funding Information

David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA


Chest. 2015;148(4_MeetingAbstracts):9A. doi:10.1378/chest.2281115
Text Size: A A A
Published online

Abstract

SESSION TITLE: Allergy and Airway Posters

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 28, 2015 at 01:30 PM - 02:30 PM

PURPOSE: The objective was to provide a summary of the real-world clinical and health economic outcomes associated with omalizumab in the treatment of moderate to severe allergic asthma.

METHODS: A systematic literature review was conducted to identify studies of omalizumab in patients ≥12 years with moderate to severe allergic asthma. A search of MEDLINE and EMBASE reference databases was conducted for relevant studies published from 2003 to 2014. Prospective observational studies, retrospective studies, meta-analyses, and health economic studies were included. Outcomes of interest included the rate or number of severe or clinically significant exacerbations and the rate, number, or costs of emergency room (ER) visits and hospitalizations. Study quality was assessed by 2 reviewers using the Newcastle-Ottawa Quality Assessment Scale of Cohort Studies.

RESULTS: A total of 42 studies were included; 24 studies evaluated asthma exacerbations, 11 evaluated ER visits and costs, and 17 evaluated hospitalizations. Statistically significant reductions in exacerbations were reported in 83% (20/24) of included studies; 18 studies utilized a pre/post design and 2 studies compared omalizumab treatment to standard of care. Significant decreases in the number of ER visits were reported in 82% of studies (9/11) across a variety of patient populations in numerous countries over 12-months. A significant reduction in hospitalizations was reported in 65% of included studies (11/17). The 2 studies that reported hospitalization costs observed a reduction in cost. Over 12 months, mean monthly hospitalization costs decreased from €133.85 to €0 (P<0.01), and the cost per inpatient day was reduced from €14,668 to €4,683 in a 6-month period. Overall, a reduction in clinically significant exacerbations, hospitalizations, including number of visits and percent of patients, and ER utilization occurred in patients utilizing omalizumab add-on therapy.

CONCLUSIONS: While patient populations and outcome definitions in these studies are heterogeneous, results from this systematic literature review suggest that patients with moderate to severe asthma using omalizumab experienced a decrease in the rate of severe exacerbations, ER visits, and hospitalizations.

CLINICAL IMPLICATIONS: Asthma patients administered omalizumab during routine clinical use experience substantial clinical and economic benefits, including a decrease in exacerbation rate, and reductions in ER and hospital utilization.

DISCLOSURE: Jonathan Corren: Consultant fee, speaker bureau, advisory committee, etc.: Novartis consultant Susan Gabriel: Employee: Employee of Novartis Tom Karagiannis: Employee: Novartis employee Kimberly Ruiz: Consultant fee, speaker bureau, advisory committee, etc.: consultant to Novartis Bethany Sawchyn: Consultant fee, speaker bureau, advisory committee, etc.: Consultant to Novartis Jennifer Colby: Consultant fee, speaker bureau, advisory committee, etc.: Consultant to Novartis Meryl Mendelson: Employee: Novartis employee

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Topics

omalizumab

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Biologics in Chronic Urticaria. Immunol Allergy Clin North Am 2017;37(1):95-112.
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543